Nymox Pharmaceutical Corporation provided updates on pivotal Phase 3 development activities for NX-1207, the company's Phase 3 drug for benign prostatic hyperplasia (BPH), a common affliction of older men. NX-1207 is also in development in Phase 2 for localized prostate cancer. The company's two large pivotal prospective double blind placebo-controlled U.S. clinical trials (NX02-0017 and NX02-0018) have completed enrollment.

One open label safety study (NX02-0020) of subjects who have received a second injection of NX-1207 has completed enrollment and 6 month data has been reported previously. A second open label reinjection study (NX02-0022) is in progress. In Europe, patient recruitment is ongoing at investigational sites in five major European countries in a Phase 3 blinded comparator-controlled clinical trial under the sponsorship of the company's European licensing partner, Recordati S.p.A. Patient participation in the NX02-0017 U.S. pivotal Phase 3 BPH study is completed.

Patient participation in the second U.S. pivotal trial, NX02-0018, will be completed in second quarter 2014. Upon completion of patient participation and blinded data verification and monitoring procedures and auditing activities, unblinding and data analyses of the two pivotal studies will commence at the appropriate time in second quarter 2014 with top line results being reported expeditiously when available.